More data is being released about Johnson and Johnson’s vaccine as they hope to become the third option seeking FDA emergency use approval in the COVID pandemic. LSU Health New Orleans School of Medicine Professor Dr. Fred Lopez said this one-dose vaccine is hopeful.
“It does look promising and I think what’s important this really does look to prevent severe illness and in many different countries where it was studied, including South Africa where there’s a variant that many people are concerned about,” said Lopez.
Lopez says data indicates the J & J vaccine is 66-percent effective at preventing moderate to severe illness from the virus and about 85-percent effective at preventing more serious illness.
“Eighty-five percent at preventing hospitalizations and deaths and that’s really what we want these vaccines to do,” said Lopez.
While the other two vaccines are two doses the J & J vaccine is one dose. Lopez said J & J’s vaccine looks just as good as the others and will be helpful in curbing the virus.
“Hopefully, there’ll be several other vaccine candidates that will be up for review and approval in the next couple of months. But this one looks good and I anticipate and expect that it will be approved,” said Lopez.
Lopez feels it will be approved by the FDA for emergency use in the near future.
Comments